Mesothelioma Clinical Trials
Mount Sinai’s mesothelioma program participates in clinical trials. These clinical trials help us develop new drugs and therapies to improve care for patients with malignant pleural mesothelioma. With clinical trials, we can test new treatments in a safe, structured way and collect data for analysis. In addition, clinical trials enable us to offer our patients access to new treatment approaches that are often not available otherwise.
Every clinical trial has specific eligibility criteria. Your doctor will determine if you are a candidate to participate and if you are likely to benefit. Clinical trials are especially important for patients whose disease does not respond to standard treatments.
Clinical Trials Open for Enrollment
The following clinical trials are open to patient enrollment:
Poly-ICLC (Hiltonol®) Vaccine in Malignant Pleural Mesothelioma
Principal Investigator: Andrea S. Wolf, MD, MPH
This clinical trial is the first of its kind to use Poly-ICLC, a synthetic vaccine, to treat malignant pleural mesothelioma. The vaccine, which does not contain live virus, has been approved by the U.S. Food and Drug Administration to help fight solid cancers like glioblastoma and melanoma. When the vaccine is injected into the tumor, it tricks the body into recognizing the cancer as foreign and prompts white blood cells and antibodies to kill it. The vaccine causes fewer side effects than many treatment drugs.
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
Principal Investigator: Jorge Gomez, MD
This trial studies how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma.